An investigational in vivo CAR-T therapy uses viral particles infused directly into the patient to convert their T-cells into CAR-T cells. This approach eliminates the complex steps of apheresis, lymphodepletion, and ex vivo manufacturing, effectively creating an off-the-shelf product that becomes an autologous treatment inside the body.

Eli Lilly’s acquisition of in-vivo CAR-T company Colonia Therapeutics signals a deliberate strategy to bypass the crowded and still unproven allogeneic cell therapy space. By investing directly in technology that modifies T-cells inside the body, Lilly is betting it can leapfrog the current generation of cell therapies toward a more scalable platform.

Many early cell therapies failed due to the impractical cost and complexity of individual manufacturing for each patient. Companies now succeeding are developing "off-the-shelf" treatments that don't require patient matching or immune suppression, creating a more scalable and commercially viable model similar to traditional drugs.

Observing that allogeneic ('off-the-shelf') cell therapies have not yet achieved their expected impact, Kite Pharma is strategically investing in in vivo approaches. Through acquisitions and partnerships, they are focusing on technologies that edit cells directly within the body, which have shown promising 'autologous-like' results.

The next frontier in cellular therapy is in-vivo CAR-T, where a gene for the CAR receptor is delivered into the patient (e.g., via mRNA lipid nanoparticles) to create CAR-T cells internally. This eliminates the complex and costly external manufacturing process, potentially creating an 'off-the-shelf' CAR-T therapy.

Early data from an in vivo CAR-T therapy suggests a paradigm shift is possible. By engineering T-cells directly inside the patient with a simple infusion, this approach could eliminate the need for leukapheresis and external manufacturing, completely disrupting the current cell therapy model.

The company's mRNA and lipid nanoparticle (LNP) platform can leverage the massive manufacturing and distribution infrastructure built globally for COVID-19 vaccines. This solves a major scalability bottleneck that plagues traditional cell therapies, making their advanced treatment potentially as accessible and distributable as a vaccine.

The commercial challenges of Bluebird Bio's "single therapy for a single patient" model were a key catalyst for the industry's evolution. This reality pushed the field toward developing more economically viable and broadly applicable technologies, like in vivo CAR-T, that can reach more patients globally.

Current cell therapies are so complex and expensive—requiring a patient's own cells—that they are only available to 20% of the people who could benefit. This massive accessibility gap is the primary driver for companies to develop "off-the-shelf" solutions using healthy donor cells.